U2AF2 drives malignant progression and chemo-resistance in hepatocellular carcinoma through cooperating with SRSF1 to modulate CCND1 splice-variant expression
Pathology - Research and Practice · 2025-12 · 276 · 156272
DOI: 10.1016/j.prp.2025.156272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2025-12. Verfasst von Peng Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400038, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Serine-Arginine Splicing Factors, Cyclin D1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Chongqing Municipal Postdoctoral Science Special Foundation, Natural Science Foundation of Chongqing Municipality.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a common malignancy with high risk of recurrence and metastasis. Growing evidences reveal that aberrant mRNA splicing represents a crucial molecular characteristic of cancer, which produces numerous and complex transcript variants to drive cancer development and progression. Here, we identified the splicing factor U2AF2 as a promising oncogenic biomarker in HCC, and subsequently explored its biological role and mechanism. Through bioinformatics analysis and clinical verification, U2AF2 was found to be significantly elevated in HCC, showing a strong correlation with the pathological grade and patient outcomes. Subsequent investigations demonstrated that U2AF2 promoted HCC growth and metastasis both in vitro and in vivo. Mechanically, U2AF2 exerted its oncogenic functions by cooperating with SRSF1 to bind to the pre-mRNA of CCND1(Cyclin D1) and facilitate the generation of CCND1b isoform. Moreover, U2AF2 could potentially be utilized for the prediction of chemo-responsiveness. Its depletion sensitized HCC cells to Doxorubicin, a first-line chemotherapy agent for advanced HCC patients. Altogether, this study deepens our understanding of U2AF2 in mRNA splicing and provides a potential therapeutic target for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400038, China.
- State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400038, China. Electronic address: 200616wy@163.com.
- State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400038, China. Electronic address: shicm@tmmu.edu.cn.
Förderung
- Chongqing Municipal Postdoctoral Science Special Foundation
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Luo, P., Dai, S., Xu, X., Liu, G., Wang, F., Li, J., Xiong, Q., Wang, Y., & Shi, C. (2025). U2AF2 drives malignant progression and chemo-resistance in hepatocellular carcinoma through cooperating with SRSF1 to modulate CCND1 splice-variant expression. Pathology - Research and Practice, 276, 156272. https://doi.org/10.1016/j.prp.2025.156272
Vancouver
Luo P, Dai S, Xu X, Liu G, Wang F, Li J, et al. U2AF2 drives malignant progression and chemo-resistance in hepatocellular carcinoma through cooperating with SRSF1 to modulate CCND1 splice-variant expression. Pathology - Research and Practice. 2025;276:156272. doi:10.1016/j.prp.2025.156272
BibTeX
@article{Luo2025,
author = {Luo, Peng and Dai, Shijie and Xu, Xingyuan and Liu, Gaoyu and Wang, Fulong and Li, Jialun and Xiong, Qin and Wang, Yang and Shi, Chunmeng},
title = {U2AF2 drives malignant progression and chemo-resistance in hepatocellular carcinoma through cooperating with SRSF1 to modulate CCND1 splice-variant expression},
journal = {Pathology - Research and Practice},
year = {2025},
volume = {276},
pages = {156272},
doi = {10.1016/j.prp.2025.156272}
}
EUVIMED